

Alexander Baldacchino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2503472/publications.pdf>

Version: 2024-02-01

37
papers

826
citations

687363

13
h-index

526287

27
g-index

39
all docs

39
docs citations

39
times ranked

1217
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: a systematic review and meta-analysis. <i>BMC Psychiatry</i> , 2014, 14, 104.	2.6	95
2	Guilty until proven innocent: A qualitative study of the management of chronic non-cancer pain among patients with a history of substance abuse. <i>Addictive Behaviors</i> , 2010, 35, 270-272.	3.0	74
3	COVID-19 and Substance Use Disorders as Brain Diseases: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine (ISAM) Practice and Policy Interest Group Position Paper. <i>Basic and Clinical Neuroscience</i> , 2020, 11, 133-150.	0.6	74
4	Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice. <i>Frontiers in Psychiatry</i> , 2019, 10, 592.	2.6	71
5	Neurocognitive consequences of chronic cannabis use: a systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 108, 358-369.	6.1	67
6	Internet pharmacies and online prescription drug sales: a cross-sectional study. <i>Drugs: Education, Prevention and Policy</i> , 2005, 12, 75-80.	1.3	66
7	Abnormal Brain Activity During a Reward and Loss Task in Opiate-Dependent Patients Receiving Methadone Maintenance Therapy. <i>Neuropsychopharmacology</i> , 2014, 39, 885-894.	5.4	54
8	Association between depression and non-fatal overdoses among drug users: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2014, 134, 12-21.	3.2	46
9	Is (poly-) substance use associated with impaired inhibitory control? A mega-analysis controlling for confounders. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 105, 288-304.	6.1	42
10	Psychological Impact of the Acute COVID-19 Period on Patients With Substance Use Disorders: We Are All in This Together. <i>Basic and Clinical Neuroscience</i> , 2020, 11, 207-216.	0.6	26
11	A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus. <i>Nature Protocols</i> , 2022, 17, 567-595.	12.0	26
12	Compulsivity in opioid dependence. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 333-339.	4.8	22
13	Association between chronic psychoactive substances use and systemic inflammation: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 125, 208-220.	6.1	13
14	Alcohol policies in Malawi: inclusion of WHO "best buy" interventions and use of multi-sectoral action. <i>BMC Public Health</i> , 2018, 18, 957.	2.9	12
15	Chronic heroin use disorder and the brain: Current evidence and future implications. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110148.	4.8	12
16	Engagement in the Overdose Risk InformatioN (ORION) e-Health Tool for Opioid Overdose Prevention and Self-Efficacy: A Preliminary Study. <i>Cyberpsychology, Behavior, and Social Networking</i> , 2017, 20, 762-768.	3.9	11
17	Alcohol Binge Drinking: Negative and Positive Valence System Abnormalities. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 126-134.	1.5	9
18	Using Microdosing to Induct Patients Into a Long-Acting Injectable Buprenorphine Depot Medication in Low Threshold Community Settings: A Case Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 631784.	3.5	9

#	ARTICLE	IF	CITATIONS
19	Harm reduction and abstinence-based models for treatment of substance use disorders during the COVID-19 pandemic: a global perspective. <i>BJPsych International</i> , 2022, 19, 66-69.	1.4	9
20	Co-Morbid Substance Misuse and Mental Health Problems: Policy and Practice in Scotland. <i>American Journal on Addictions</i> , 2007, 16, 147-159.	1.4	8
21	Professionalsâ€™ Digital Training for Child Maltreatment Prevention in the COVID-19 Era: A Pan-European Model. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 885.	2.6	8
22	Baseline executive functions and receiving cognitive rehabilitation can predict treatment response in people with opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108558.	2.8	7
23	Quantifying prescribed high dose opioids in the community and risk of overdose. <i>BMC Public Health</i> , 2021, 21, 1174.	2.9	6
24	Protracted abstinence in males with an opioid use disorder: partial recovery of nucleus accumbens function. <i>Translational Psychiatry</i> , 2022, 12, 81.	4.8	6
25	COVID-19 and Substance Use Disorder: Study Protocol for the International Society of Addiction Medicine Practice and Policy Interest Group Global Survey. <i>Basic and Clinical Neuroscience</i> , 2020, 11, 155-162.	0.6	5
26	Ophthalmic outcomes in children exposed to opioid maintenance treatment in utero: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 136, 104601.	6.1	5
27	Pathways through care for people with dual diagnosis in Europe: results from the Treatment Options for Dual Diagnosis User Zoom instrument. <i>Mental Health and Substance Use: Dual Diagnosis</i> , 2011, 4, 195-210.	0.5	4
28	Investigating the effect of Alcohol Brief Interventions within accident and emergency departments using a data informatics methodology. <i>Drug and Alcohol Dependence</i> , 2018, 188, 47-52.	3.2	2
29	Adherence to Prescribed Acamprosate in Alcohol Dependence and 1-Year Morbidities and Mortality: Utilizing a Data Linkage Methodology. <i>Journal of Clinical Medicine</i> , 2021, 10, 2102.	2.4	2
30	Understanding Fatal and Non-Fatal Drug Overdose Risk Factors: Overdose Risk Questionnaire Pilot Studyâ€™ Validation. <i>Frontiers in Pharmacology</i> , 2021, 12, 693673.	3.5	2
31	Chronic pain, prescribed opioids and overdose risk: a qualitative exploration of the views of affected individuals and family members. <i>Drugs: Education, Prevention and Policy</i> , 2023, 30, 229-240.	1.3	2
32	Co-morbidity of substance use and mental disorders. What do we know on the prevalence of psychiatric comorbidity in Europe and what are the ways forward?. <i>Mental Health and Substance Use: Dual Diagnosis</i> , 2013, 6, 97-100.	0.5	1
33	Development of an algorithm to classify primary care electronic health records of alcohol consumption: experience using data linkage from UK Biobank and primary care electronic health data sources. <i>BMJ Open</i> , 2022, 12, e054376.	1.9	1
34	A comparison of accidental and intentional fatal drug overdoses within the drug death population in Scotland: a case of comortality?. <i>Mental Health and Substance Use: Dual Diagnosis</i> , 2011, 4, 5-21.	0.5	0
35	Cognitive consequences of opioid use. , 2020, , 179-198.		0
36	An international consultation on case reports in addiction medicine. <i>Substance Abuse</i> , 2021, 42, 1-7.	2.3	0

#	ARTICLE	IF	CITATIONS
37	Why Do Different Forms of Knowledge Matter in Evidence-Based Drug Policy?. American Journal of Public Health, 2022, 112, S140-S142.	2.7	0